Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD — The Con Argument | Zendy

Jeremy Road | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD — The Con Argument

Author(s) -

Jeremy Road

Publication year - 2004

Publication title -

canadian respiratory journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.675

H-Index - 53

eISSN - 1916-7245

pISSN - 1198-2241

DOI - 10.1155/2004/284010

Subject(s) - medicine , copd , quality of life (healthcare) , pulmonary disease , randomized controlled trial , intensive care medicine , inhaled corticosteroids , physical therapy , asthma , nursing

The management of patients with symptomatic chronic obstructive pulmonary disease (COPD) has become more clear in the past several years. New medications have been developed and their efficacy has been evaluated using important outcomes in addition to forced expiratory volume in 1 s (FEV1), such as health-related quality of life (HRQL), frequency of exacerbations and dyspnea scores. I will review five welldesigned, randomized, controlled trials that have advanced our knowledge about the use of inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs) and their combination

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research